Synergistic action of GLP-1 and SGLT2 Inhibition in Cardiometabolic Disease

Background: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) are two novel classes of glucose-lowering agents with proven cardiometabolic benefits beyond glycaemic control. Both are now recommended in international guidelines for patients with type 2 diabetes mellitus (DM2) and high cardiovascular risk. As they operate through complementary mechanisms, their combined use may confer additive or synergistic benefits on cardiometabolic outcomes. Aim: This narrative review examines and synthesizes the available evidence on the synergistic effects of GLP-1 RAs and SGLT2 inhibitors in cardiometabolic disease, encompassing their effects on glycaemic control, body weight, blood pressure, cardiovascular events, renal outcomes, and mortality. Methods: A narrative review of randomized clinical trials, observational studies, post-hoc analyses, and meta-analyses evaluating the combination of GLP-1 RAs and SGLT2 inhibitors in patients with DM2 was conducted. Individual drug class evidence from landmark cardiovascular and renal outcome trials is also reviewed to contextualize the potential for synergy. Results: The combination of GLP-1 RAs and SGLT2 inhibitors consistently produced greater reductions in HbA1c (−1.0% to −1.5%), body weight (−3 to −9 kg), and systolic blood pressure (−4 to −10 mmHg) compared with either agent alone across multiple randomized trials, including DURATION-8, AWARD-10, SUSTAIN-9, and LIRA-ADD2SGLT2. Observational studies suggest a significant reduction in major adverse cardiovascular events and heart failure hospitalizations with combination therapy. However, randomized trial data do not consistently confirm a superiority in cardiovascular event rates. Effects on renal outcomes are inconsistent across studies. Combination therapy appears well tolerated, with no significant increase in serious adverse events beyond those expected from each agent individually. Conclusions: The combination of GLP-1 RAs and SGLT2 exerts additive benefits on glycaemic control, body weight, and blood pressure reduction. Evidence for synergistic cardiovascular and renal protection is promising but remains limited, largely derived from observational data and secondary analyses. Larger, dedicated randomized trials are needed to determine whether combination therapy confers superior cardiometabolic outcomes beyond either agent alone.